# Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

> **NCT04308174** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Asan Medical Center** · enrollment: 45 (actual)

## Conditions studied

- Biliary Tract Neoplasms
- Gallbladder Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** Durvalumab + Gem/Cis
- **DRUG:** Gem/Cis

## Key facts

- **NCT ID:** NCT04308174
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-20
- **Primary completion:** 2023-06-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04308174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04308174, "Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04308174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*